• Strong organic revenue growth of 11.0% in the first quarter and revenue of CHF 680.7 million
• Varied regional growth dynamics persist, with EMEA and APAC regions outperforming
• Straumann and SprintRay collaborate to drive unique chairside workflow with 3D printing
• Global launch of Straumann iEXCEL and EMEA launches of UNIQ and Falcon
• Outlook 2025 confirmed: the Group aims to achieve organic revenue growth in the high single-digit percentage range, with a 30 to 60 basis points improvement of the core EBIT margin at constant 2024 currency rates

REVENUE BY REGION
(in CHF million)	Q1 2025	Q1 2024[1]
Europe, Middle East & Africa (EMEA)	280.0	258.4
Change in CHF (in %)	+8.4	+2.5
Change in local currencies (in %)	+10.0	+12.0
Change organic[2] (in %)	+10.0	+9.2
% of Group total	41.1	41.8
North America (NAM)	185.1	177.8
Change in CHF (in %)	+4.1	-2.3
Change in local currencies (in %)	+1.8	+3.7
Change organic2 (in %)	+1.8	+3.7
% of Group total	27.2	28.7
Asia Pacific (APAC)	162.2	130.8
Change in CHF (in %)	+24.0	+63.7
Change in local currencies (in %)	+23.0	+84.2
Change organic2 (in %)	+23.0	82.0
% of Group total	23.8	21.1
Latin America (LATAM)	53.4	51.4
Change in CHF (in %)	+3.9	+8.8
Change in local currencies (in %)	+18.8	+11.5
Change organic2 (in %)	+18.8	+11.5
% of Group total	7.8	8.3
GROUP	680.7	618.3
Change in CHF (in %)	+10.1	+10.2
Change in local currencies (in %)	+11.0	+19.1
Change organic2 (in %)	+11.0	+17.5

 

Basel, April 30, 2025: Straumann Group started strongly into the year with a revenue of CHF 680.7 million in the first quarter and an organic growth of 11.0% or 10.1% in Swiss francs. While varied regional growth dynamics persisted and macroeconomic uncertainties continued to impact customer demand, the regions EMEA and APAC both stood out. EMEA, the largest region, achieved double-digit growth and APAC was again the biggest contributor to organic revenue growth, thanks to the continued solid patient flow in China.

Across the regions, growth was mainly driven by both premium and challenger segments, supported by an overall double-digit growing orthodontics business and positive contribution from the digital business. At the well-attended International Dental Show (IDS) in Cologne in March 2025, one of the largest dental fairs globally, the Group’s broad range of innovations including new launches drew strong interest and received highly positive feedback.

 

Guillaume Daniellot, Chief Executive Officer, said: “I’m proud of our team and the strong momentum we have built, driven by our high-performance, player-learner culture — a key element in helping us stay agile and adapt in a fast-changing environment. While macroeconomic uncertainties continue to impact businesses globally, we are well positioned — both in terms of our diversified portfolio and broad geographic presence — to build on our strengths and drive long-term success. I’m very pleased with the results we have achieved as a team and the positive reception at the IDS fair. The wealth of innovations we launched, our strategic collaborations, and our continued investments in growth reflect our commitment to shaping the future of dentistry and strengthening our foundation for the years to come. With these achievements, and despite the fact that macroeconomic challenges will remain, we confirm our 2025 outlook.”

 

REGIONAL PERFORMANCES

 

Strong growth in Europe, Middle East and Africa

The Group’s largest region, Europe, Middle East, and Africa (EMEA), reported revenue of CHF 280.0 million, representing 10.0% organic growth. Germany, the region’s largest market, continued its strong growth trajectory, with Italy, Spain, and Belgium also making notable contributions to the excellent revenue performance. The Group gained further market share in both the premium and challenger implant segments, supported by the continued strength of its premium brand and the successful reception of the newly launched iEXCEL implant system. Challenger brands like Neodent and Anthogyr also further deepened their presence across the region. In addition, double-digit growth from the ClearCorrect orthodontics brand, alongside solid performance in biomaterials, contributed to the region’s excellent results.

 

North America with low single-digit growth

In the first quarter, the North America region reported revenue of CHF 185.1 million, delivering 1.8% organic growth in a soft implantology market in the US, according to Group estimates. The Group achieved positive growth despite a macroeconomic environment which led consumers to be more cautious with their spending in the first quarter, affecting patient flow. The premium brand Straumann showed a positive performance supported by the growing traction of the recently launched Straumann iEXCEL implant system. The Neodent brand posted solid growth during the first quarter, while the orthodontics business remained soft. Finally, the digital business contributed to the positive growth, driven by the successfully launched UN!Q prosthetics service and intraoral scanners.

 

Asia Pacific continued its growth path against a strong comparison basis

The Asia Pacific region achieved a historical high with CHF 162.2 million in revenue and an organic growth of 23.0% against a strong comparison base. Once more, the growth in China stood out, driven by the long-lasting structural impact of the volume-based procurement (VBP) initiative that boosted awareness and made implants affordable. In addition to strong double-digit growth in emerging markets like Thailand, India, and Malaysia, developed markets such as Australia and Japan sustained their growth momentum. The implantology business remained the primary growth driver, with both premium and challenger brands playing an instrumental role. Neodent performed very well in Australia, Thailand and India. Digital solutions made a meaningful contribution to the overall regional performance, supported by the launch of the SIRIOS intraoral scanner across the region. 

 

Latin America – consistently strong double-digit growth

In the first quarter, the Latin America region reported revenue of CHF 53.4 million, demonstrating a strong organic growth of 18.8%. The implant business, notably the challenger brand Neodent, remained the primary growth driver, with markets like Brazil and Mexico showing strong revenue growth. The premium segment saw accelerated growth thanks to targeted initiatives. Furthermore, the ClearCorrect business also delivered an impressive performance, with Brazil and Mexico as main revenue contributors. Finally, the digital business, particularly the SIRIOS intraoral scanners, contributed strongly to the consistent double-digit regional growth.

 

STRATEGIC PROGRESS / NEWS HIGHLIGHTS

 

Straumann Group presented its advanced digital dentistry end-to-end workflow at IDS

In March, at the International Dental Show (IDS) in Cologne, one of the largest dental fairs globally, Straumann presented innovative solutions aiming to help clinicians deliver better care with increased efficiency. The Group unveiled its most advanced digital dentistry innovations to date, emphasizing a fully integrated end-to-end workflow through its cloud-based platform, Straumann AXS. Now fully launched across Europe, the Middle East, and Africa, AXS unites key solutions including Smile-in-a-Box and the newly introduced UN!Q prosthetics service, providing seamless connectivity from diagnostics to treatment execution. Clinicians can now benefit from a streamlined digital ecosystem that integrates intraoral scanning with SIRIOS, AI-powered surgical planning via coDiagnostiX, and comprehensive digital workflows that reduce complexity and enhance patient outcomes.

 

At IDS, Straumann announced strategic collaborations to drive unique digital workflows

In a move to redefine chairside care, Straumann Group announced its strategic collaboration with SprintRay, a leading innovator in 3D printing technology based in Los Angeles, US. The co-branded Straumann Signature Midas printer enables dental professionals to print prosthetic components — including crowns, inlays, and onlays — in under 10 minutes, and is connected to the Straumann AXS platform and SIRIOS intraoral scanner. The collaboration with SprintRay marks a pivotal step in digital dentistry by allowing for efficient, digitally connected workflows for single-visit treatments at an attractive price point. This collaboration was very well perceived — much like the partnership between Straumann Group and Carestream Dental, a leading provider of Cone Beam Computed Tomography (CBCT) systems. The strategic collaboration with Carestream Dental will enable the seamless integration of CBCT imaging into the AXS platform and simplify the transition from diagnostics to guided surgery.

 

Global launch of Straumann iEXCEL and EMEA launches of UNIQ and Falcon

Also at IDS, Straumann Group announced the global launch of its high-performance implant system iEXCEL, following its successful introduction in North America. Combining four implant designs into one streamlined system with a single instrument kit and the TorcFit connection, iEXCEL features the clinically proven Roxolid material and SLActive surface to support minimally invasive procedures and faster osseointegration. Straumann also introduced two key innovations in EMEA: the launch of Falcon, its first compact dynamic navigation system for real-time surgical guidance, and the European launch of UN!Q, a cloud-based on-demand prosthetics service that enables dental labs to outsource the design and production of patient-specific restorations. All three solutions were met with strong interest from IDS attendees, highlighting Straumann’s commitment to delivering integrated, efficient digital workflows.

 

The Annual General Meeting approved all proposals including the dividend increase

At the Annual General Meeting on April 10, 2025, the shareholders of Straumann Holding AG approved all of the Board’s proposals. The increased cash dividend of CHF 0.95 per share was paid on April 16, 2025.

 

OUTLOOK 2025 CONFIRMED – BARRING UNFORESEEN EVENTS

 

The Group anticipates that macroeconomic uncertainties will persist and continue to impact demand across various regions. However, thanks to its strong innovation capabilities, the broad global footprint also in terms of manufacturing sites, a differentiated global value proposition at various price points, and consistent execution driven by a strong culture, the Group remains confident in its ability to continue gaining market share within its estimated global addressable market of approximately CHF 20 billion. In addition, the Group emphasizes its ongoing investments in regional production capacity, digital transformation and extensive training initiatives, enabling more clinicians to perform implant and orthodontic procedures. As a result, the Group aims to achieve organic revenue growth in the high single-digit percentage range, with a 30 to 60 basis points improvement of the core EBIT margin at constant 2024 currency rates.

 

###

 

If you want to learn more about the innovations launched at the IDS in Cologne in March 2025, please follow this link.

 

^[1] Adjusted figures referring to continuing operations, following the agreement signed in August 2024 to sell the Group’s DrSmile business to Impress Group; the sale was completed in September 2024.

 

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland   

 Phone: +41 (0)61 965 11 11

Homepage: www.straumann-group.com

 

Contacts:

Corporate Communication Silvia Dobry: +41 (0)61 965 15 62 Frank Keidel: +41 (0)61 965 19 76 E-mail: corporate.communication@straumann.com	Investor Relations Marcel Kellerhals: +41 (0)61 965 17 51 Derya Güzel: +41 (0)61 965 18 76 E-mail: investor.relations@straumann.com

ANALYSTS’ AND MEDIA CONFERENCE CALL

Straumann will present its 2025 first-quarter results to representatives of the financial community and media in a webcast conference call today at 10.30 a.m. CEST.

 

The webcast can be accessed via www.straumann-group.com/webcast. A replay of the webcast will be available after the conference.

 

If you intend to ask a question during the Q&A, we kindly ask you to pre-register for the conference call through this link. We also recommend that you download the presentation file in advance using the direct link in this media release before joining the conference call.

 

Presentation

The conference presentation slides are attached to this release and available on the Media and Investors pages at www.straumann-group.com.

 

 

UPCOMING CORPORATE / INVESTOR EVENTS

 

2025	Event	Location
6 - 7 May	Berenberg Roadshow	London
8 – 9 May	Kepler Cheuvreux Roadshow	Amsterdam
12 May	Bernstein Roadshow	Madrid
13 May	BofA Global Healthcare Conference	Las Vegas
20 May	Equita Roadshow	Dublin
28 – 29 May	Stifel Jaws and Paws Conference	New York
4 – 5 Jun	Jefferies Global Healthcare Conference	New York
1 July – 12 August	Quiet period
13 August	Second quarter 2025 results	Webcast

 

 

Disclaimer

This press release contains forward-looking statements, including statements regarding the beliefs, expectations and assumptions of future results, performance or achievements of Straumann Group, that are based upon information available to Straumann Group as of the date such statements are made. Forward-looking statements are neither historical facts nor assurances of future performance. They may, but need not, be identified by words such as: "anticipate," "intend," "plan," "goal," "believe," "project," "estimate," "expect," "future," "likely," "may," "should," "will" and similar references to future periods or events. Such forward-looking statements reflect the views, beliefs, assumptions and expectations of Straumann Group or its management at the time the statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may be outside of Straumann Group’s control. Such known and unknown risks, uncertainties and other factors underlying forward-looking statements may cause the actual results, performance or achievements of the Group to differ materially from those expressed or implied in this document. Accordingly, you should not rely on any forward-looking statements contained in this press release. Important factors that could cause the Group’s expectations regarding future results, performance or achievements to differ materially from those expressed in a forward-looking statement include, but are not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann Group's control. Should one or more of these risks, uncertainties or other factors materialize or should underlying views, beliefs, assumptions or expectations prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann Group is providing the information in this release as of the date it is issued and does not undertake any obligation to update any statements as a result of new information, future events or otherwise.This release constitutes neither an offer to sell nor a solicitation to buy any securities.